Mesentech has a proprietary bone targeting technology that can deliver small molecules directly to bone. Our candidate products are all prodrugs of compounds that have validated efficacy but too much systemic toxicity to get through clinical development. Our conjugation technology selectively liberates the active molecule in bone in a controlled slow-release manner. Our first product is a bone-targeted version of MK0987, a potent bone-anabolic. We're currently in IND enabling tox. Our second compound is a bone-targeted anti prostate cancer agent.